Navigation Links
Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
Date:5/20/2008

94 Percent of Men Maintained Normal Testosterone Levels Throughout

Treatment

92 Percent of Men Expressed Satisfaction with NEBIDO

LEXINGTON, Mass., May 20 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that data on NEBIDO(R) (testosterone undecanoate), an investigational, long-acting intramuscular injection for the treatment of hypogonadism, was presented in a late breaker presentation at the 2008 American Urological Association Annual Meeting held in Orlando. The data, which had been previously announced, are based on a Phase III study in which men with hypogonadism and low serum testosterone levels prior to entering the study were treated with NEBIDO for 24 weeks. This study demonstrated that 94 percent of the men had their testosterone levels restored and maintained to within normal levels; further, 92 percent of these men expressed satisfaction with their NEBIDO treatment. Sixty-two percent of men participating in the Phase III study had previously used other testosterone treatments.

"An estimated four to five million men in the U.S. suffer from a common but treatable condition called hypogonadism, or low testosterone. Men with this condition experience decreased libido, fatigue, depression, and muscle loss," said Abraham Morgentaler, MD, Associate Clinical Professor of Urology at Harvard Medical School. "Low testosterone is associated with other significant health issues including diabetes, obesity, cardiovascular disease, and osteoporosis. Low testosterone is under-recognized and under-treated. Results of a Phase III study on a long-acting testosterone injection called testosterone undecanoate (NEBIDO) revealed that a very high pe
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
2. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
3. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
4. Indevus Announces Submission of New Drug Application
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
7. Napo Presents at ISPOR Meeting in Toronto
8. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
9. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... CITY , Aug. 27, 2014 Varian Medical ... expand its current Salt Lake City ... underway outside of Utah to ultimately ... the next 20 years. " Utah ... and technical talent, many of whom can be credited with ...
(Date:8/27/2014)... 27, 2014   Los Angeles orthodontics expert, ... to patients who want to make their treatment even ... the OrthoSpaceship, all patients have a powerful tool to ... can be used by most patients with all types ... by using the AcceleDent® Aura system for a few ...
(Date:8/27/2014)... August 27, 2014 According ... Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental Lasers), Current Trends, ... MarketsandMarkets, the global Dental Equipment Market is expected to ... in 2014, growing at a CAGR of 5.7% ... market data tables and 61 figures spread through ...
Breaking Medicine Technology:Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 4Los Angeles Orthodontist, Dr. Isaac Hakim, is Now Offering AcceleDent Aura 2Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3
... 22, 2011 Mylan Inc. (Nasdaq: MYL ... of the Mylan Institutional business, has entered a license ... treatment products company, for the exclusive U.S. distribution rights ... Netherlands, has a portfolio that includes products used by ...
... 2011 Auxilium Pharmaceuticals, Inc. (Nasdaq: ... today that they have entered into a long-term ... of XIAFLEX® (collagenase clostridium histolyticum), a novel, first-in-class ... Peyronie,s disease.  Under the terms of the agreement, ...
Cached Medicine Technology:Mylan Announces Exclusive Distribution Partnership with Humeca to Expand Burn and Wound Care Portfolio 2Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan 2Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan 3Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan 4Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan 5Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan 6Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan 7
(Date:8/28/2014)... 28, 2014 Registration is now open ... Warriors® in Holmdel, New Jersey on Sunday, October 19, ... the New Jersey Vietnam Veterans’ Memorial adjacent to the ... Bank Arts Center. All proceeds of the event will ... to restoring a sense of self, restoring the family ...
(Date:8/28/2014)... 2014 An unprecedented service that finds local ... 9 Spine offers their resources online and in person. ... a brick wall of discouragement as activities and hobbies are ... Cloud 9 Spine offers a refreshing plan of action. ... interaction that sets Cloud 9 Spine apart from other service ...
(Date:8/28/2014)... Alpine, NJ resident Othon Mourkakos is proud to ... Tiaras, to benefit the Immune Deficiency Foundation (IDF) Walk ... in Foley Square, New York. IDF is the ... (PI) are a group of more than 200 rare, ... immune system is missing or functions improperly. In ...
(Date:8/28/2014)... IL (PRWEB) August 28, 2014 The ... the healthcare industry from the time a patient books ... and insurance company provide final payments for services rendered ... based medical billing service has the RCM process ... software programs and computers become common place in nearly ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 Aeroflow ... to acquire as part of a strategic expansion ... is positioned for taking ownership of new businesses ... increase economies of scale. , Last week, the ... with Hometown Respiratory to increase service in the ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Announces Second Annual NJ Run 2Health News:Making Waves on the East Coast, Cloud 9 Spine is Helping Patients Find Appointments With Local Spine Doctors 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 3Health News:Aeroflow Healthcare Seeks Strategic Acquisition Opportunities 2
... able to stop or even slightly improve the progression ... to implant // embryonic cells into their brains, say ... that helps control movement. People with Parkinson’s don’t produce ... in people with the condition. ,Researchers compared 20 ...
... of Pittsburgh Medical Center treated 33 prostate cancer patients, ... Patients received the same radiation doses that patients in ... study show the elderly patients had a five-year survival ... patients experienced no unusual or prolonged breaks in treatment ...
... to cancer-causing pollutants found in the air, report researchers ... .Past studies in mice have shown exposure to pollutants ... the fact the placenta filters out most of the ... in humans. ,Researchers collected blood samples from 265 ...
... United States suffer from erectile dysfunction. This causes a ... and weight loss // , obese men with erectile ... say researchers. ,Researchers, conducted a study to determine ... increase in physical activity, would improve obese men’s erectile ...
... not decrease, but may increase, the risk for dementia ... an association between postmenopausal estrogen use and lower risk ... estrogen plus progestin in women aged 65 to 79 ... estrogen-only trial, researchers found 47 participants were diagnosed with ...
... 20s could reduce the risk of developing high blood pressure ... with spikes in blood pressure are more likely to have ... ,Specialists say assessing blood pressure changes in response to stress ... risk of high blood pressure. In a large study more ...
Cached Medicine News:
Patient-Centered Therapy that promotes natural cardiac function....
The ACP 215 is the automated closed system cell processor with integrated process control....
... Durability for Excellent Access. Access ... challenging cases. PT² wires combine ... linear elastic nitinol distal core ... tip. This provides excellent access ...
... The PCS2 system ... for the collection of ... allow for the collection ... platelet-poor plasma, platelet-poor plasma ...
Medicine Products: